Epidemiology & Risk Factors

  • Pathogenesis: Collection of purulent material in the space between the renal capsule and Gerota’s fascia.
    • Ascending UTI/pyelonephritis with rupture of an intrarenal cortical abscess into the perirenal fat (most common, >75%).
    • Hematogenous seeding (e.g., S. aureus bacteremia from IV drug use, endocarditis).
  • Risk Factors:
    • Diabetes Mellitus (DM) (present in up to 30-40% of cases).
    • Nephrolithiasis or obstructive uropathy.
    • Anatomical urinary tract abnormalities (e.g., vesicoureteral reflux).
    • Prior urological instrumentation or surgery.
    • Immunosuppression.
  • Common Pathogens:
    • Escherichia coli (most common overall).
    • Proteus mirabilis, Klebsiella pneumoniae.
    • Staphylococcus aureus (in hematogenous cases).

Clinical Features

  • History:
    • Insidious onset (>1-2 weeks) of fatigue, weight loss, night sweats, or low-grade fevers.
    • Persistent fever and flank pain (>4-5 days) despite appropriate IV antibiotic therapy for pyelonephritis.
    • Lower urinary tract symptoms (dysuria, frequency, urgency) are not always present (often absent if the abscess does not communicate with the collecting system).
  • Physical Examination (PE):
    • High-grade fever, chills, and rigors.
    • Unilateral costovertebral angle (CVA) tenderness.
    • Palpable flank or abdominal mass (in up to 30-40% of cases).
    • Ipsilateral scoliosis due to psoas muscle spasm.

Diagnosis

  • Initial/Screening:
    • Renal Ultrasound (US): Useful first-line in pregnant/pediatric patients or in emergency settings. Shows a hypoechoic or anechoic perirenal fluid collection with possible internal debris or septations. Less sensitive for small (<3 cm) abscesses.
  • Confirmatory/Gold Standard:
    • Contrast-Enhanced CT of Abdomen and Pelvis: Diagnostic test of choice. Shows a well-defined, hypodense perirenal fluid collection with a ring-enhancing capsule/rim after IV contrast. May reveal gas-fluid levels or underlying nephrolithiasis.
  • Key Labs:
    • CBC: Markedly elevated WBC (leukocytosis) with left shift.
    • BMP: Checked to monitor renal function (Creatinine/BUN).
    • Urinalysis (UA) & Urine Culture: Normal UA in up to 30% of cases (if no communication with collecting system). c
    • Blood Cultures: Positive in up to 50% of cases; mandatory to evaluate for urosepsis or hematogenous spread.
    • Inflammatory Markers: Elevated ESR and CRP.
  • Biopsy/Aspiration:
    • Ultrasound- or CT-guided fine-needle aspiration of pus for Gram stain and culture (essential for targeting therapy).

Differential Diagnostics

  • Acute Pyelonephritis:
    • Differentiating features: Pyelonephritis typically responds to appropriate IV Abx within 48-72 hours, whereas perinephric abscess features persistent fever despite treatment. UA is almost always positive in pyelonephritis; CT in pyelonephritis shows wedge-shaped perfusion defects rather than a localized perirenal fluid collection.
  • Renal Abscess (Intrarenal):
    • Differentiating features: Collection is completely confined to the renal parenchyma without breaching the renal capsule. Usually smaller and less associated with psoas spasm.
  • Renal Cell Carcinoma (RCC):
    • Differentiating features: Pt presents with a flank mass, hematuria, and flank pain but typically lacks acute infectious signs (fever, leukocytosis). CT shows a solid, hypervascular tissue mass rather than a rim-enhancing fluid collection.
  • Emphysematous Pyelonephritis:
    • Differentiating features: Severe, life-threatening necrotizing infection. CT shows gas within the renal parenchyma (rather than fluid/pus in the perinephric space).

Management

  1. First-line / Immediate Stabilization:
    • Fluid resuscitation (IVF) and supportive care for sepsis if hemodynamically unstable.
    • Broad-spectrum IV Empiric Antibiotics:
      • Must cover Gram-negative bacilli and S. aureus. E.g., Piperacillin-Tazobactam (Zosyn), Carbapenem (e.g., Meropenem), or Cefepime + Vancomycin (if MRSA suspected).
      • If abscess is small (<3 cm) and patient is stable, may attempt IV Abx alone.
  2. Second-line / Definitive Intervention:
    • Percutaneous Drainage (PCD):
      • Indicated for abscesses >3 cm or for smaller abscesses failing to respond to 48-72 hours of IV Abx.
      • Pus must be sent for Gram stain, culture, and sensitivity.
  3. Refractory / Surgical Intervention:
    • Surgical Drainage / Open Debridement: Indicated if PCD fails, if the abscess is multiloculated, or if there is extensive contiguous spread.
    • Nephrectomy: Indicated if the affected kidney is non-functioning (<15% function on differential renogram), has severe parenchymal destruction, or in refractory urosepsis.

Complications

  • Sepsis and Septic Shock (secondary to urosepsis).
  • Abscess Rupture:
    • Into the peritoneal cavity (causing peritonitis).
    • Into the pleural space (causing empyema).
  • Renal Parenchymal Destruction leading to chronic kidney disease (CKD) or end-stage renal disease (ESRD).
  • Psoas Abscess: Spread of infection along the psoas muscle.
  • Fistula Formation (e.g., nephrobronchial, nephroenteric).